Inventor · disambiguated record
William A. Gahl
Also filed as: GAHL WILLIAM A
8 granted patents·3 pending applications·10 citations·filing 2008–2019
80Inventor score
Files withUS HEALTH6HUIZING MARJAN2BROOKS BRIAN P1GAHL WILLIAM A1US OF AMERICA AS REPRESENTATED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES1
Top patents by PatentIndex Score
11 records- 0174US8410063B2N-acetyl mannosamine as a therapeutic agentHUIZING MARJAN·Filed 2008·Granted Apr 2, 2013·4 cites·20 claims
- 0269US9095597B2N-acetyl mannosamine as a therapeutic agentUS HEALTH·Filed 2013·Granted Aug 4, 2015·1 cites·9 claims
- 0365US9341619B2Hyposialylation disordersUS OF AMERICA AS REPRESENTATED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2014·Granted May 17, 2016·2 cites·19 claims
- 0465US8822540B2Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentationBROOKS BRIAN P·Filed 2011·Granted Sep 2, 2014·3 cites·15 claims
- 0564US10953026B2N-acetyl mannosammine as a therapeutic agentUS HEALTH·Filed 2019·Granted Mar 23, 2021·0 cites·16 claims
- 0659US10335426B2N-acetyl mannosammine as a therapeutic agentUS HEALTH·Filed 2017·Granted Jul 2, 2019·0 cites·9 claims
- 0752US9364448B2Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentationUS HEALTH·Filed 2014·Granted Jun 14, 2016·0 cites·19 claims
- 0849US2015290229A1N-acetyl mannosammine as a therapeutic agentUS HEALTH·Filed 2015·Application pending·0 cites
- 0935US2013109645A1Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disordersGAHL WILLIAM A·Filed 2011·Application pending·0 cites
- 1033US2013058998A1Encapsulated n-acetylmannosamine or n-acetylneuraminic acid to increase sialylationHUIZING MARJAN·Filed 2012·Application pending·0 cites
- 1131US11155521B2Cannabinoid receptor mediating compoundsUS HEALTH·Filed 2016·Granted Oct 26, 2021·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when William A. Gahl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →